Study Identifies Mechanisms of Heart Disease Progression and Reversibility in Myotonic Dystrophy Type 1

Baylor Researchers Uncover DM1 Heart Disease Progression and Potential for Reversal

Researchers at Baylor College of Medicine have investigated the progression and potential for reversal of heart disease associated with Myotonic dystrophy type 1 (DM1). The study, published in the Journal of Clinical Investigation Insight, found that cardiac complications in DM1 can worsen over time due to prolonged exposure to toxic RNA, even without further genetic mutation expansion.

Findings also suggest that early intervention may lead to significant recovery of heart function, while delayed treatment could result in irreversible damage.

Understanding Myotonic Dystrophy Type 1 and Cardiac Impact

Myotonic dystrophy type 1 (DM1) is a genetic disorder recognized as the most common cause of adult-onset muscular dystrophy. It leads to progressive muscle weakness and affects multiple organ systems, including the brain, gastrointestinal tract, and heart. Cardiac manifestations, primarily electrical conduction abnormalities and arrhythmias, are present in up to 75% of adult DM1 patients and account for 25% of mortality, making them the second leading cause of death in individuals with the condition.

DM1 is caused by a mutation in the DMPK gene, characterized by an expanded triplet repeat sequence (CTG). While unaffected individuals typically have 5 to 37 repeats, those with DM1 can exhibit 50 to over 4,000 repeats. This genetic alteration results in the production of faulty RNA molecules that sequester muscleblind-like (MBNL) proteins. The loss of MBNL protein function, which is crucial for normal RNA processing and gene splicing, is considered a primary driver of DM1 pathogenesis.

Unraveling Disease Progression: Insights from an Animal Model

To understand how cardiac disease in DM1 progresses, researchers utilized an animal model where toxic RNA was consistently expressed over time, but without the expansion of CTG repeats. Key observations from this model included:

• Early Onset: Mice developed enlarged hearts and significant electrical abnormalities at an early stage.
• Continued Worsening: Over a period of up to 14 months, the mice's hearts weakened, progressing to severe arrhythmias, fibrosis (scarring), and dilation of heart chambers.
• Reduced Lifespan: Mice exposed to long-term toxic RNA had shorter lifespans, with males particularly affected.
• Molecular Stability: Abnormal RNA splicing, a molecular consequence of DM1, appeared early but did not worsen over time. This finding suggests that disease progression in this model was not solely due to increasing loss of MBNL function.
• Proposed Mechanism: Researchers propose that prolonged exposure to the toxic RNA leads to cumulative damage to the heart, resulting in structural remodeling and declining function.

Can Cardiac Damage Be Reversed?

The study also explored whether cardiac damage could be reversed by deactivating the toxic RNA in the animal model.

• Short-term Exposure: When the toxic RNA was turned off after a brief period of expression, heart size, electrical function, and structure largely returned to normal.
• Long-term Exposure: After many months of toxic RNA exposure, deactivation resulted in significant but incomplete recovery. While abnormal RNA splicing fully corrected, physical changes such as thickened heart walls, conduction delays, and fibrotic scar tissue often did not fully reverse. This incomplete reversal was particularly noted in male mice.

Fibrosis is considered concerning due to its impact on electrical signaling and increased risk of deadly arrhythmias.

Sex Differences in DM1 Cardiac Disease

The research identified clear sex differences consistent with observations in human DM1 patients. Male mice generally developed more severe heart disease, exhibited worse rhythm disturbances, and showed less complete recovery after the toxic RNA was turned off. These findings highlight the importance of further research into how biological sex influences heart disease risk and treatment response in DM1.

Critical Implications for DM1 Patient Care

These findings indicate that heart disease in DM1 can progress due to prolonged exposure to toxic RNA, even in the absence of additional genetic repeat expansion.

The study underscores that early intervention can reverse many cardiac problems, whereas delayed treatment may allow damage to accumulate, becoming more resistant to reversal.

The research emphasizes the importance of early monitoring and timely treatment of cardiac symptoms in DM1 patients to achieve better health outcomes.